NASDAQ:ALLO

Allogene Therapeutics Stock Insider Trading

etoro logo Buy ALLO
*Your capital is at risk
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026

Allogene Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 42.16. In total, the insiders bought 19.78M and sold 730.17K ALLO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
42.16
Buy 19.78M shares
Sell 730.17K shares
66% Buy Activity
Moderate Positive Correlation
Sell Signal Low Confidence
Mar 16, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 42.16.
  • Partially supported by a positive historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Apr 21, 2026
Sell
Common Stock
S-Sale
Yoshiyama Annie
SVP, Finance
Officer 9 586
Value: $22.1K
Mar 31, 2026
Sell
Common Stock
S-Sale
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 2 867
Value: $7K
Mar 16, 2026
Sell
Common Stock
S-Sale
Chang David D
President And CEO
CEO / President 47 763
Value: $118.0K
Mar 16, 2026
Sell
Common Stock
S-Sale
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 4 835
Value: $11.9K
Mar 02, 2026
Sell
Common Stock
S-Sale
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 7 132
Value: $18.5K
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Belldegrun Arie
Director
Director 929 913
Value: $1.74M
Feb 02, 2026
Sell
Common Stock
S-Sale
Roberts Zachary
EVP Of R&d
Officer 35 700
Value: $63.2K
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Yoshiyama Annie
SVP, Finance
Officer 50 827
Value: $95.0K
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Yoshiyama Annie
SVP, Finance
Officer 179 691
Value: $336.0K
Feb 02, 2026
Sell
Common Stock
S-Sale
Douglas Earl Martin
SVP, General Counsel
Officer 22 900
Value: $40.3K
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Parker Geoffrey M.
Chief Financial Officer
C-Suite Officer 152 480
Value: $285.1K
Feb 02, 2026
Sell
Common Stock
S-Sale
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 7 549
Value: $13.1K
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 373 757
Value: $698.9K
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Beneski Benjamin Machinas
SVP, Chief Technical Officer
Officer 105 720
Value: $197.7K
Feb 02, 2026
Sell
Common Stock
S-Sale
Chang David D
President And CEO
CEO / President 95 269
Value: $171.5K
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Chang David D
President And CEO
CEO / President 1 387 931
Value: $2.60M
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Chang David D
President And CEO
CEO / President 392 586
Value: $734.1K
Feb 02, 2026
Sell
Common Stock
S-Sale
Parker Geoffrey M.
Chief Financial Officer
C-Suite Officer 24 001
Value: $42.2K
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Parker Geoffrey M.
Chief Financial Officer
C-Suite Officer 539 072
Value: $1.01M
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Douglas Earl Martin
SVP, General Counsel
Officer 539 072
Value: $1.01M
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Douglas Earl Martin
SVP, General Counsel
Officer 152 480
Value: $285.1K
Feb 02, 2026
Sell
Common Stock
S-Sale
Yoshiyama Annie
SVP, Finance
Officer 4 167
Value: $7K
Feb 02, 2026
Buy
Stock Option (Right to buy)
A-Award
Roberts Zachary
EVP Of R&d
Officer 718 763
Value: $1.34M
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Roberts Zachary
EVP Of R&d
Officer 203 307
Value: $380.2K
Feb 02, 2026
Buy
Restricted Stock Unit
A-Award
Belldegrun Arie
Director
Director 263 033
Value: $491.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ALLOGENE THERAPEUTICS INC.
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE